Latest Breaking News On - Advanced gastric - Page 2 : comparemela.com

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® using PD-L1 IHC 22C3 pharmDx .

Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers

BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets

16.10.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines . Seite 1